The treatment of a subgroup of breast tumors resistant to targeted therapies - named triple-negative tumors because of a lack of estrogen, progesterone, and HER2/Neu receptors - is a problem that remains unsolved [1,2]. Here, ERBB2 is linked to breast neoplasm.